Merck (MRK) Beats Stock Market Upswing: What Investors Need to KnowZacks Investment Research • 10/06/26
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa StudyZacks Investment Research • 10/01/26
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)Business Wire • 09/30/26
Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology PipelineZacks Investment Research • 09/29/26
Merck Turned $1,000 Into $3,395 in a Decade but the Real Story Happened in the Last Year24/7 Wall Street • 09/29/26
AstraZeneca Digs $2 Billion Out Of Its Coffers For Summit Deal, Taking On Bristol, Pfizer, MerckInvestors Business Daily • 09/29/26
FDA Expands Merck's Welireg Label for a New Kidney Cancer IndicationZacks Investment Research • 09/28/26
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) InhibitorBusiness Wire • 09/28/26
Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily WithdrawnBusiness Wire • 09/25/26
Merck's Remigromig Meets Main Goal in Diabetic Macular Edema StudyZacks Investment Research • 09/25/26
U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)Business Wire • 09/25/26